LACRINORM 0,2% Ophthalmic gel tube/10g

VIDAL
Medicines
Update of 10/07/2025

LACRINORM^®
carbomer 980

Forms and presentations

Ophthalmic gel at 0,2 %:  Tube of 10 g.

Composition

	tube
Carbomer (carbopol 980)	20 mg

Excipients: sorbitol, benzalkonium chloride, sodium hydroxide, water for injection.

Excipient with known effect: benzalkonium chloride.

This medicine contains 0,1 mg of benzalkonium chloride per gram of ophthalmic gel.

Indications

Symptomatic treatment of dry eye syndrome.

Dosage and administration

Ophthalmic use.

Instill one drop of ophthalmic gel into the lower conjunctival sac 3 to 4 times a day, or more, depending on the severity of symptoms.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section Composition.

Warnings and precautions

• Wearing soft contact lenses should be avoided during the course of treatment due to the risk associated with the presence of benzalkonium chloride.
  
• If concomitant treatment with another eye drop is given, wait 15 minutes between the two instillations.
  
• Do not touch the eye with the tip of the tube.
  
• Replace the cap on the tube after use.
  
• In the absence of specific studies, the use of this ophthalmic gel is not recommended in children.
  
• This medicine contains 0,1 mg of benzalkonium chloride per gram of ophthalmic gel.
  
• Benzalkonium chloride may be absorbed by soft contact lenses and change their colour. Remove contact lenses before application and wait at least 15 minutes before reinserting them.
  
• Benzalkonium chloride may also cause eye irritation, especially if the patient has dry eye syndrome or corneal disorders. If abnormal sensation, tingling or pain in the eyes occurs after using this medicine, a doctor should be consulted.
  

Interactions

If concomitant treatment with another eye drop is given, wait 15 minutes between the two instillations.

Fertility, pregnancy and breastfeeding

Given the available data, use in pregnant or breastfeeding women is possible.

Driving and using machines

Vision may be blurred for a few minutes after instillation.

Adverse effects

Possibility of:

• vision trouble;
  
• transient, passing burning sensation after instillation until the gel spreads evenly over the surface of the eye;
  
• sensation of sticky eyelids;
  
• irritation or hypersensitivity reactions.
  
• due to the presence of benzalkonium chloride, risk of contact eczema, irritation and bronchospasm.
  

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals should report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres. Website: https://signalement.social-sante.gouv.fr.

Overdose

In case of overdose, rinse with sterile physiological saline.

Pharmacodynamics

Pharmacotherapeutic class: lacrimal substitute, ATC code: S01XA20 (S: sensory organs).

• Ophthalmic gel based on a high molecular weight hydrophilic polymer (carbomer 980).
  
• This gel forms a transparent, lubricating and wetting film on the surface of the eye, which temporarily compensates for insufficient tears.
  
• Its pH and osmolarity are similar to those of the normal tear film.
  

Pharmacokinetics

In rabbits, the residence time on the surface of the eye is on the order of 40 minutes.

Penetration through the cornea seems unlikely due to the large size of the molecule.

Preclinical safety

No safety problems were detected during the development of this medicinal product. The ingredients have a well-established use in ophthalmology.

Storage conditions

Store at a temperature not exceeding 25 °C.

HANDLING/DISPOSAL INSTRUCTIONS

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Prescription, supply and reimbursement

Marketing authorisation (AMM)

3400933666644 (1994, SmPC rev 04.09.2023).

Price:	2,71 euros (10 g tube).
Reimbursed by Social Security at 65 %. Collective.

CHAUVIN Laboratory
416, rue Samuel-Morse. CS 99535. 34961 Montpellier
Tel: 04 67 12 30 30